Work Type: Fixed-term - Full-time
Salary: $142,790 - $191,084
Grade: VPS 6
Occupation: Other
Location: Melbourne - CBD and Inner Metro suburbs
Reference: VG/102704
Senior Business Development Manager, Pipeline Access and Transition
The Role
mRNA Victoria is seeking an experienced Senior Business Development Manager, Pipeline Access and Transition to drive key business development activities associated with the BioNTech R&D and Clinical Scale mRNA Manufacturing Facility Project and support the establishment and transition to a proposed new State Company. With a scientific background and understanding of drug development pathways, you will lead market engagement, pipeline development, commercial agreements and access arrangements for manufacturing and translation services. You will build and maintain relationships across industry, universities, medical research institutes and government, monitor global mRNA and biotechnology developments, identify opportunities for grant funding and provide expert advice on complex commercial and strategic matters.
Main Accountabilities
The Team
The position of Senior Business Development Manager, Pipeline Access and Transition forms part of mRNA Victoria within the Industry, Trade and Investment Group.
The Industry, Trade and Investment group works closely with businesses locally and globally to grow Victorian jobs, drive innovation and increase Victoria's international competitiveness. It supports trade and international investment, international education and innovation, while developing Victoria's priority sectors, boosting trade activities and enhancing productivity and economic growth.
mRNA Victoria is leading the Victorian Government's commitment to establish a world-class Australian mRNA vaccine and therapeutic industry by supporting supply chain, research and development, commercialisation and global commercial manufacturing investments. It leads the Moderna population scale vaccine manufacturing partnership, the BioNTech clinical mRNA manufacturing partnership and other ecosystem-building initiatives in Victoria.
About You
You will bring strong business and commercial acumen, with the ability to drive value and return on investment, consider economic indicators and manage organisational risk. You will communicate with impact by identifying key messages, providing high-level advice and tailoring content and style to different audiences. You will also bring strong project delivery capability, including the ability to consider broader context, inform project direction and mitigate risk. Experience in business development within the biotech industry, relationships with the local and international mRNA industry, and experience in grant management and oversight are highly desirable. Experience valuing pharmaceutical assets would also be beneficial.
Further Information
For a confidential discussion, please contact Damian Dewar, Snr Advisor Projects and Investment, on 0409 240 369 or [email protected] .
The Department is committed to creating and maintaining a child safe organisation. We have zero tolerance of child abuse and are committed to taking the necessary steps to protect children from harm by adopting a preventative, proactive and participatory approach to child safety in accordance with the Child Safe Standards.
Successful candidates will be required to undergo a National Police Records Check prior to commencing employment with the Department.
The Department is committed to inclusive recruitment. If you require an adjustment to participate in any stage of the recruitment process or have a particular requirement to be communicated with by either telephone or email only, please notify the DJSIR Talent Acquisition Team on 0472 875 685, or via email at [email protected] with the position number in the subject line.
How to Apply
Please click the ‘Apply Now' button. As part of the application process, you will need to provide a copy of your resume and a cover letter addressing the key selection criteria outlined in the position description.
Applications close at 23:59pm on 13 October 2026.